|
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical research trials and Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies clinical trial. Participants frequently obtain the most expert healthcare available for their Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies  Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
For Condition: Lymphoma,Wilms' Tumor,Leukemia,Soft Tissue Sarcoma,Osteosarcoma
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The goal of this clinical research study is to learn if treatment with the drug liposomal vincristine can shrink or slow the growth of the patient's cancer. The safety of this drug will also be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with relapsed malignancies in the following strata: (As of 09/01/02, the soft tissue sarcoma strata will remain open for new patient accrual. Strata listed in b, c, d, e will be closed to entry). a. soft tissue sarcoma b. bone sarcoma(CLOSED TO ENTRY AS OF 09/01/02) c. Wilms tumor(CLOSED TO ENTRY AS OF 09/01/02) d. lymphoma(CLOSED TO ENTRY AS OF 09/01/02) e. leukemia(CLOSED TO ENTRY AS OF 09/01/02) - Performance status: Zubrod less than 3. Patients with long standing limited mobility requiring the use of a wheelchair will be considered ambulatory for the purpose of this protocol. - Bidimensionally measurable disease radiologically. - No anti-cancer treatment within the past 3 weeks. - ANC greater than or equal to 500; platelets greater than or equal to 50,000; bilirubin less than or equal to 1.5 mg/dl; SGPT less than or equal to 4 x upper normal limit; creatinine less than or equal to 2 x normal. Patients with bone marrow infiltrative disease may be entered irrespective of ANC or platelets. - Minimum life expectancy of greater than or equal to 8 weeks. - Patients may be enrolled after BMT or PSCT if they meet all the above eligibility criteria. Exclusion criteria: - HIV positive. - Serious intercurrent illness, active infections, or second cancer except basal cell carcinoma of the skin or cervical carcinoma in situ. - Eligible for treatment of a higher priority. - Pregnancy. - Grade 3 or 4 sensory or motor dysfunction due to prior vinca alkaloids.
Total Enrollment: 100
Location and Contact Information:
M. D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Cynthia Herzog 713-745-0157
Additional Information:
Study ID Numbers: P99-401;
Study Start Date: June 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038207
Other Lymphoma Studies:
1. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
2. Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
Related Studies:
Other Lymphoma Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
|
|
|
|
|
|
|
|
